Literature DB >> 22468635

Drug safety evaluation of pregabalin.

Cory Toth1.   

Abstract

INTRODUCTION: Pregabalin is an anticonvulsant with one known mechanism of action which is used most specifically in the management of neuropathic pain. AREAS COVERED: The adverse effect profile of this medication from controlled, randomized studies as well as open and long-term studies is described with consideration of the evidence-based results for pregabalin's clinical use. EXPERT OPINION: Pregabalin is a mostly well tolerated medication for the management of neuropathic pain and other conditions. Pregabalin use is associated with benign central nervous system and systemic adverse effects with very limited metabolic, idiosyncratic, or teratogenic adverse effects. Understanding of these adverse effects is essential for the clinician treating the patient and for the patient receiving treatment. Sedation, dizziness, peripheral edema, and dry mouth are the most prevalent adverse events experienced in all clinical populations. Other adverse effects are rare, but are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22468635     DOI: 10.1517/14740338.2012.677026

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  11 in total

1.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

2.  Peripheral edema with pregabalin.

Authors:  Romayne Gallagher; Nicole Apostle
Journal:  CMAJ       Date:  2012-11-05       Impact factor: 8.262

Review 3.  Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.

Authors:  Cory Toth
Journal:  Ther Adv Drug Saf       Date:  2014-02

4.  Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.

Authors:  Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen
Journal:  J Am Soc Nephrol       Date:  2018-06-05       Impact factor: 10.121

5.  A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

Authors:  Stefania Chiappini; Fabrizio Schifano
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

6.  Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems.

Authors:  Jan Schjøtt; Jenny Bergman
Journal:  Drug Healthc Patient Saf       Date:  2014-07-01

7.  Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.

Authors:  Burak Kulaksızoğlu; Hüseyin Kara; Berkan Bodur; Murat Kuloğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-09       Impact factor: 2.570

8.  Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury.

Authors:  Daniele Tomassoni; Francesco Amenta; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Innocent E Nwankwo; Alessandra Pacini; Seyed Khosrow Tayebati
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

9.  A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.

Authors:  Rainer Freynhagen; Michael Serpell; Birol Emir; Ed Whalen; Bruce Parsons; Andrew Clair; Mark Latymer
Journal:  Pain Pract       Date:  2013-11-27       Impact factor: 3.183

10.  Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials.

Authors:  Harsha Shanthanna; Ian Gilron; Lehana Thabane; Philip J Devereaux; Mohit Bhandari; Rizq AlAmri; Manikandan Rajarathinam; Sriganesh Kamath
Journal:  BMJ Open       Date:  2016-11-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.